RAS-MAPK-MSK1通路调节了SCA1中的ATAXIN 1蛋白水平和毒性
Jeehye Park1,2,3, Ismael Al-Ramahi1,2, Qiumin Tan1,2,3
1Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas 77030, USA.
Nature
|May 31, 2013
概括
研究人员确定了一种针对RAS-MAPK-MSK1通路的遗传网络,以降低1型脊髓小脑动症 (SCA1) 中的有毒蛋白质水平. 这一发现为SCA1和类似的神经退行性疾病提供了新的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 神经退行性疾病,如阿尔茨海默氏症,帕金森症和多重胺胺疾病,都有一个共同的病理:致病蛋白质的异常积累.
- 这种积累是由于蛋白质降解受损或野生类型蛋白质过度表达造成的.
- 确定调节这些蛋白质水平的治疗点对于治疗这些难以治愈的疾病至关重要.
研究的目的:
- 开发和应用查策略,以识别影响疾病驱动蛋白质水平的遗传网络.
- 为了发现神经退行性疾病的新型治疗入口点,使用脊髓小脑动症1型 (SCA1) 作为模型.
- 在临床前模型中验证已识别的目标,并评估其治疗潜力.
主要方法:
- 综合并行基于细胞和Drosophila的基因查,以确定影响素1 (ATXN1) 水平的遗传网络.
- 利用了ATXN1.1.1中多重氨胺通道扩张引起的1型脊髓小脑动脉动脉 (SCA1) 的疾病模型.
- 在Drosophila和小鼠模型中测试了已识别的途径组件的药理抑制剂的影响.
主要成果:
- 基因选显示,RAS-MAPK-MSK1通路中的组件的下调显著降低了ATXN1蛋白水平.
- 降低ATXN1水平导致SCA1.1在Drosophila和小鼠模型中抑制神经退行.
- 关键途径组件的药理抑制也表现出类似的效果,降低了ATXN1水平.
结论:
- RAS-MAPK-MSK1通路代表了1型脊髓小脑动症 (SCA1) 的新型治疗标.
- 该途径的药理向为缓解SCA1提供了一个有希望的策略.
- 这种方法为开发其他难治的神经退行性疾病的治疗方法提供了原则证明,其特点是蛋白质聚合.
相关概念视频
01:42Microtubule Associated Proteins (MAPs)
4.8K
Microtubule function and architecture are regulated by an array of specialized proteins called microtubule-associated proteins or MAPs. These proteins are widespread across different organisms and have conserved protein motifs, like the multi-TOG domain for tubulin binding found in the CLASP family of MAPs. Some MAPs are lineage-specific based on their conserved domains. Their functions depend upon the cytoskeletal architecture and cell type they are located within. In-plant cells, a specific...
4.8K
01:19Interactions Between Signaling Pathways
4.7K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
4.7K
01:07MAPK Signaling Cascades
7.4K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.4K
01:20The JAK-STAT Signaling Pathway
10.3K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
10.3K